-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Benzinga·10/02/2026 13:06:59
語音播報
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.